Phio pharmaceuticals corp. (PHIO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Sep'11Jun'11
Revenues

0

21

21

78

136

138

0

0

0

-

0

0

-

19

19

19

10

34

0

0

0

-

-

-

-

-

-

-

0

-

0

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86

162

375

399

427

0

0

-

0

-

-

-

-

Operating expenses:
Research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Research and development employee stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Research and development non-employee stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Research and development

4,429

4,300

4,221

4,017

4,054

4,326

4,586

5,238

5,384

5,370

5,473

5,447

5,457

5,415

5,831

6,101

6,123

6,925

6,764

6,489

6,311

5,680

5,556

5,326

5,356

17,651

17,349

17,334

23,068

10,451

10,441

11,019

0

0

0

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

4,696

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

General and administrative expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

General and administrative employee stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Common stock warrants issued for general and administrative expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

General and administrative

4,768

4,708

3,852

3,492

3,353

3,176

3,188

3,463

3,789

4,011

4,241

4,007

3,792

3,619

3,486

3,504

3,423

3,346

3,205

3,201

3,247

3,217

3,569

3,737

3,864

3,697

3,202

2,807

2,546

2,621

3,047

3,554

0

0

0

Total operating expenses

9,197

9,008

8,073

7,509

7,407

7,502

7,774

8,701

9,258

14,077

14,410

14,150

13,860

9,034

9,317

9,605

9,546

10,271

9,969

9,690

9,558

8,897

9,125

9,063

9,220

21,348

20,551

20,141

25,614

13,072

0

0

0

-

0

Operating loss

-9,197

-8,987

-8,052

-7,431

-7,271

-7,364

-7,621

-8,605

-9,220

-14,062

-14,410

-14,150

-13,851

-9,015

-9,298

-9,586

-9,536

-10,237

-9,921

-9,626

-9,482

-8,826

-9,039

-8,901

-8,845

-20,949

-20,141

-19,766

-25,464

-12,975

-13,431

0

0

0

-

Interest (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

15

21

25

22

16

12

8

12

17

25

25

0

-

0

0

-

-

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8

-30

0

0

0

-

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

6

4

0

0

-

-

0

-

-

0

0

-

-

0

51

121

125

247

1,149

0

0

0

Total other income, net

57

79

77

57

31

4

-14

-13

-11

-11

0

4

7

21

27

31

27

14

11

18

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-14,073

-14,410

-14,146

-13,844

-8,994

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for income taxes

-

-

-

-

-

-

-

-

-

-1,621

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-9,140

-8,908

-7,975

-7,374

-7,240

-7,360

-7,635

-8,618

-9,231

-12,452

-12,789

-12,525

-12,223

-8,994

-9,271

-9,555

-9,509

-10,223

-9,911

-9,621

-9,461

-8,800

-9,004

-8,857

-8,812

-20,925

-20,128

-19,713

-25,351

-12,880

-13,212

-13,450

0

0

0

Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

209

671

1,371

2,560

4,130

0

0

0

-

-

-

-

-

-

-

-

-

-

Series A and Series A-1 convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,670

17,843

0

-

0

0

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,432

-10,582

-10,992

-12,021

-12,930

-13,889

-14,489

-15,630

-29,535

-28,439

-27,854

-41,713

-25,695

-25,109

-24,070

0

0

0

Net loss per share: Basic and diluted

-1.33

-13.46

-0.08

-0.08

-5.71

-55.76

-0.34

-0.46

-0.90

-0.70

-1.05

-1.12

-2.65

-6.26

-3.36

-3.38

-3.41

0.10

-0.38

-0.50

-1.32

-7.18

-0.17

-0.23

-0.32

0.57

-0.30

-0.39

-2.76

-0.89

-0.56

-4.13

-0.04

-0.05

-0.05

Weighted average shares: basic and diluted

1,772

-48,163

25,409

24,226

371

-10,455

4,371

4,102

2,494

2,383

2,351

2,238

2,057

733

657

653

653

6,591

6,494

4,419

2,376

-37,580

17,494

14,015

12,616

11,761

11,630

11,168

6,496

-47,958,849

5,238

4,406

47,967,499

41,970

38,568